Because, ICIs were the common treatment for HCC in clinical practice, we investigated whether this signature was associated with ICIs-related molecules and found that the high-risk group was positively related with PDCD1, CD274, CTLA4, HAVCR2, and LAG3 (Figure 4(b)). Here, CTLA4 is linked to hepatocellular carcinoma.